Clinical Trial Update: Vaginal Progesterone to Reduce the Risk of Another Preterm Birth [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating vaginal progesterone to reduce the risk of another preterm birth in pregnant women with a history of preterm birth has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Preterm Birth

Drugs mentioned

• Vaginal progesterone (progesterone)

Snippet

Sponsor: Juniper Pharmaceuticals, Inc. | Conditions: Pregnancy | Phase 3 | Status: COMPLETED